Recent

% | $
Quotes you view appear here for quick access.

Arrowhead Research Corp. Message Board

  • paul.thiebor paul.thiebor Jan 31, 2013 2:30 PM Flag

    Cerulean Announces First Patient Dosed in Randomized Phase 2 Study of CRLX101 in Advanced Small Cell Lung Cancer

    CAMBRIDGE, Mass.--(BUSINESS WIRE)--Cerulean Pharma Inc., a leader in developing dynamically tumor-targeted nanopharmaceuticals, today announced that the first patient has been dosed in a randomized Phase 2 study of its lead candidate, CRLX101, in patients with extensive-stage small cell lung cancer (SCLC) sensitive to first-line platinum-based chemotherapy.

    “This randomized study should answer the question of whether CRLX101 can meaningfully impact an area of severely unmet medical need.”

    With the 150-patient randomized Phase 2 study in advanced non-small cell lung cancer expected to read out soon, Cerulean is broadening the CRLX101 opportunity in lung cancer.

    Will this news benefit ARWR stock price?

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Starting soon, Cerulean as a good royalty trigger for ARWR.

      Why? Cerulean has - for the moment - 5 Programs running. Randomized non small cell lung cancer (NSCLC, data out soon in Q1 2013), ovarian cancer, renal cell cancer (avastin combo), gastric cancer, randomized SCLC with topotecan, and don't forget soon the IND for CRLX301.

      I'am sure that the data on the randomized NSCLC are very good, otherwise they wouldn't go forward so fast with the other programs!

      The siRNA-platform is licensed from ARWR, as it is CRLX101. ARWR has the rights to get royalties in the range from 10-40%. For Ceruleans CEO, the IPO- environment is encouraging...

      They also will get royalties from CLRX-301 (same siRNA-Platform).

      ARWR is a RNAi-platform(+)-company, but only since the Roche-deal a year ago. They are moving fast in the clinic. This is not a binary company like Celsion (CLSN). Till july they will have enough cash, but after that, they need CASH from big pharma for a long waited RNAi-partnership. And I a sure they will get at least one - see page 22 on there CP.
      Maybe I'am too confident - like the longs on CLSN have been. RNAi has just so much potential. And so - for me - ARWR too. Biotech is not done in one year!

      Sentiment: Strong Buy

    • unclear whether they get a milestone on this development..arwr's 10-K is vague as to which developments trigger milestones and which do not...certainly good ancillary news for arwr.

 
ARWR
6.10-0.09(-1.37%)Jul 30 4:00 PMEDT